PRE
Prenetics Global Limited
NASDAQ · Healthcare · Medical - Diagnostics & Research · HK
$25.41
−0.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
Market Cap
$435.59M
MomentumView details →
1D Return
−0.86%
YTD Return
+61.44%
RSI (14)
66.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
Market Cap
$435.59M
RSI (14)
66.8
MomentumView details →
1D Return
−0.86%
YTD Return
+61.44%
SummaryUpdated Jun 1, 2026
Prenetics Global Limited (NASDAQ:PRE) is a Hong Kong-based diagnostics and genetic testing company founded in 2014 that went public in July 2021. The company operates as an investment holding company with subsidiaries focused on developing and commercializing consumer genetic testing products, rapid diagnostic tests, and health monitoring systems. Prenetics has positioned itself in the growing personalized healthcare market, offering direct-to-consumer genetic testing alongside point-of-care diagnostic solutions.
Similar companies
Latest newsMore news →
Prenetics Global Limited CEO Danny Yeung and CFO Brian Rosin purchased $1.0 million of the company's ordinary shares in the open market between August 20 and August 25, 2026, following the release of second quarter 2026 financial results.9d agoPrenetics Global Limited held its Q2 2026 earnings call on August 22, 2026.13d agoPrenetics announced it will report its Q2 2026 financial results on August 18, 2026, and will live-stream the earnings event on Stocktwits.28d ago